Clinical Trials Logo

Filter by:
NCT ID: NCT02981576 Completed - Clinical trials for Spinal Cord Injuries

Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Spinal Cord Injury (SCI) is a devastating condition that leads to permanent functional and neurological deficits in injured individuals. The limited ability of the Central Nervous System (CNS) to spontaneously regenerate impairs axonal regeneration and functional recovery of the spinal cord. The leading causes are motor-vehicle crashes, sports-associated accidents, falls, and violence-related injuries. Unfortunately, there is still no effective clinical treatment for SCI. In recent years, tissue engineering and regenerative medicine based approaches have been proposed as alternatives for SCI repair/regeneration. Mesnchymal stem cells (MSC) use in SCI showed promising results in several studies. Our aim is to assess and compare the safety and effectiveness of autologous BM-MSC vs autologous AT-MSC in these patients.

NCT ID: NCT02979912 Completed - Clinical trials for Persistent Corneal Epithelial Defect

Autologous Platelet Lysate in Corneal Epithelial Defects

Start date: February 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.

NCT ID: NCT02977312 Completed - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

CCMLJ
Start date: August 2012
Phase: N/A
Study type: Observational

This study assessed the efficacy and safety of generic imatinib in patients with chronic myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label, prospective study combined with retrospective data collection from files of patients with a diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s) additional to the daily practice were performed

NCT ID: NCT02949804 Completed - Vasovagal Syncope Clinical Trials

Relation Between Vasovagal Tendency and Smoking Among University Students

Start date: December 2016
Phase: N/A
Study type: Observational

Almost everyone is aware these days is aware about the risk of smoking. Still many people start this habit specially in early life and during college year. We aim to investigate in this study if there is a drive to smoke in people with vasovagal tendency to improve their symptoms, even if not aware of this. Vasovoagal symptoms are common and include dizziness, smoking, sweating, abdominal pain, fatigue and syncope. Some studies have shown correlation between smoking and a positive tilt table test which is indicative of vasovagal tendency. By collecting the information regarding smoking habit and vasovagal symptoms analysis can be done to see if there is correlation between these two factors

NCT ID: NCT02945449 Completed - Clinical trials for Erectile Dysfunction Associated With Type 2 Diabetes Mellitus

Safety of Wharton Jelly in Erectile Dysfunction

Start date: January 4, 2017
Phase: Phase 1
Study type: Interventional

Safety of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.

NCT ID: NCT02941926 Completed - Breast Cancer Clinical Trials

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

COMPLEEMENT-1
Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..

NCT ID: NCT02826408 Completed - Signs and Symptoms Clinical Trials

Effect of Proton Pump Inhibitors on Palpitations

Start date: October 2016
Phase: N/A
Study type: Interventional

Palpitation is a common complaint. Patients frequently feel this symptom despite having normal rhythm during symptoms. I have seen many patients who improve significantly on treatment with proton pump inhibitors (PPI). It may be that gastritis provokes a feeling of discomfort that subsequently starts the feeling of palpitation. On searching literature I found no study that investigated the effect of PPI's on palpitations. Therefore I propose a study where the investigators randomize people with palpitations with normal heart rate (no arrhythmia) and no apparent cause such as anxiety or clear illness to receive either PPI or placebo. The result will help to investigate if the improvement is true and if the results are positive this can provide a simple treatment for a common problem.

NCT ID: NCT02751931 Completed - Clinical trials for Neurogenic Detrusor Overactivity

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Crocodile
Start date: June 17, 2016
Phase: Phase 3
Study type: Interventional

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

NCT ID: NCT02744144 Completed - Wounds and Injuries Clinical Trials

Wound Bacterial Microbiota and Their Antibiotic Resistance

Start date: September 2014
Phase: N/A
Study type: Observational

The purpose of the study is to explore the microbiology in war-associated wounds of hospitalized patients from the Syrian armed conflict. Cultures collected from acute wounds with clinical signs of infection will be analyzed.

NCT ID: NCT02741596 Completed - Clinical trials for Hereditary Angioedema (HAE)

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Start date: May 26, 2016
Phase: Phase 3
Study type: Interventional

This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.